Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Osmotica Pharmaceuticals plc is a biotechnology business based in the US. Osmotica Pharmaceuticals shares (OSMT) are listed on the NASDAQ and all prices are listed in US Dollars. Osmotica Pharmaceuticals employs 302 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$1.94|
|52-week range||$1.84 - $6.38|
|50-day moving average||$2.90|
|200-day moving average||$3.15|
|Wall St. target price||$5.50|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.45|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-13)||-3.48%|
|1 month (2021-09-20)||-35.12%|
|3 months (2021-07-20)||-46.11%|
|6 months (2021-04-20)||-36.18%|
|1 year (2020-10-20)||-66.78%|
|2 years (2019-10-18)||-57.27%|
|3 years (2018-10-19)||9.03|
|5 years (2016-10-16)||N/A|
Valuing Osmotica Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Osmotica Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Osmotica Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $33 million.
The EBITDA is a measure of a Osmotica Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$189.9 million|
|Operating margin TTM||7.13%|
|Gross profit TTM||$103.4 million|
|Return on assets TTM||2.12%|
|Return on equity TTM||-77.1%|
|Market capitalisation||$161.6 million|
TTM: trailing 12 months
There are currently 562,916 Osmotica Pharmaceuticals shares held short by investors – that's known as Osmotica Pharmaceuticals's "short interest". This figure is 1% up from 557,454 last month.
There are a few different ways that this level of interest in shorting Osmotica Pharmaceuticals shares can be evaluated.
Osmotica Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Osmotica Pharmaceuticals shares currently shorted divided by the average quantity of Osmotica Pharmaceuticals shares traded daily (recently around 131830.44496487). Osmotica Pharmaceuticals's SIR currently stands at 4.27. In other words for every 100,000 Osmotica Pharmaceuticals shares traded daily on the market, roughly 4270 shares are currently held short.
However Osmotica Pharmaceuticals's short interest can also be evaluated against the total number of Osmotica Pharmaceuticals shares, or, against the total number of tradable Osmotica Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Osmotica Pharmaceuticals's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Osmotica Pharmaceuticals shares in existence, roughly 10 shares are currently held short) or 0.0185% of the tradable shares (for every 100,000 tradable Osmotica Pharmaceuticals shares, roughly 19 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Osmotica Pharmaceuticals.
Find out more about how you can short Osmotica Pharmaceuticals stock.
We're not expecting Osmotica Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Osmotica Pharmaceuticals's shares have ranged in value from as little as $1.84 up to $6.38. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Osmotica Pharmaceuticals's is 2.2519. This would suggest that Osmotica Pharmaceuticals's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary. The company's promoted products include M-72, a methylphenidate hydrochloride extended-release tablet to treat attention deficit hyperactivity disorder (ADHD); Osmolex ER, an amantadine extended-release tablet for the treatment of Parkinson's disease and drug-induced extrapyramidal reactions in adults; Arbaclofen extended-release tablets which is in phase III clinical trial for the treatment of multiple sclerosis spasticity; Upneeq, an oxymetazoline hydrochloride ophthalmic solution for the treatment of Blepharoptosis; and OS870 which is in Phase I clinical trial for the treatment of neurodegenerative disorders. It also provides women's health products, including Divigel for menopause; and OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods. In addition, the company's non-promoted products comprise methylphenidate ER tablets for ADHD; venlafaxine ER tablets to treat major depressive disorders and social anxiety disorders; hydromorphone ER for treating pain; nifedipine ER for hypertension; sodium benzoate/sodium phenylacetate for the treatment of hyperammonemia; oxybutynin ER for overactive bladder; prescription prenatal vitamins for treating nutritional requirements during pregnancy; Lorzone, an immediate-release form of chlorzoxazone indicated for the treatment of acute musculoskeletal pain in conjunction with rest and physical therapy; ConZip, a tramadol hydrochloride for the management of pain; and nitrofurantoin for the treatment of urinary tract infections, as well as Osmodex and other abbreviated new drug applications. Osmotica Pharmaceuticals plc is headquartered in Bridgewater, New Jersey. .
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.